Sera Prognostics, Inc., (SERA) News
Filter SERA News Items
SERA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SERA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SERA News From Around the Web
Below are the latest news stories about SERA PROGNOSTICS INC that investors may wish to consider to help them evaluate SERA as an investment opportunity.
Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceSera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco. Zhenya Lindgardt, President and CEO, will present on January 16 at 9:45 a.m. PT and provide a company update and discuss Sera's latest achievements. |
With 40% stake, Sera Prognostics, Inc. (NASDAQ:SERA) seems to have captured institutional investors' interestKey Insights Institutions' substantial holdings in Sera Prognostics implies that they have significant influence over... |
Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy MeetingSera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting™ on January 31, 2025 at 10:15 a.m. MT. Dr. Brian Iriye – maternal-fetal medicine expert at the High Risk Pregnancy Ce |
Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare ConferenceSera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 2:30 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements. |
5 investing trends for 2025—and 15 stocks to help you bet on themHow to play AI, luxury goods, defense, and more. (And while you're at it: Buy gold.) |
Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumSera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements. |
Sera Prognostics (NASDAQ:SERA) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, Sera... |
Sera Prognostics Third Quarter 2024 Earnings: Misses ExpectationsSera Prognostics ( NASDAQ:SERA ) Third Quarter 2024 Results Key Financial Results Net loss: US$7.92m (loss widened by... |
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue EstimatesSera Prognostics (SERA) delivered earnings and revenue surprises of -9.09% and 67.78%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTSSera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. |